vs

Side-by-side financial comparison of CHICAGO RIVET & MACHINE CO (CVR) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $6.0M, roughly 1.1× CHICAGO RIVET & MACHINE CO). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -19.3%, a 32.2% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 45.9%). CHICAGO RIVET & MACHINE CO produced more free cash flow last quarter ($24.3K vs $-5.3M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -12.7%).

Chicago Pneumatic, also known as "CP", is an industrial manufacturer providing power tools, air compressors, generators, light towers and hydraulic equipment. Products are sold in more than 150 countries through a worldwide distribution network. CP is active on markets such as tools for industrial production, vehicle service, maintenance repair operation for mining, construction, infrastructure equipment.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

CVR vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.1× larger
LCTX
$6.6M
$6.0M
CVR
Growing faster (revenue YoY)
LCTX
LCTX
+84.5% gap
LCTX
130.4%
45.9%
CVR
Higher net margin
LCTX
LCTX
32.2% more per $
LCTX
12.9%
-19.3%
CVR
More free cash flow
CVR
CVR
$5.3M more FCF
CVR
$24.3K
$-5.3M
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-12.7%
CVR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVR
CVR
LCTX
LCTX
Revenue
$6.0M
$6.6M
Net Profit
$-1.2M
$851.0K
Gross Margin
2.7%
Operating Margin
-15.3%
-99.1%
Net Margin
-19.3%
12.9%
Revenue YoY
45.9%
130.4%
Net Profit YoY
68.0%
126.0%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVR
CVR
LCTX
LCTX
Q4 25
$6.0M
$6.6M
Q3 25
$7.4M
$3.7M
Q2 25
$7.3M
$2.8M
Q1 25
$7.2M
$1.5M
Q4 24
$4.1M
$2.9M
Q3 24
$7.0M
$3.8M
Q2 24
$8.1M
$1.4M
Q1 24
$7.9M
$1.4M
Net Profit
CVR
CVR
LCTX
LCTX
Q4 25
$-1.2M
$851.0K
Q3 25
$67.6K
$-29.8M
Q2 25
$-395.0K
$-30.5M
Q1 25
$401.0K
$-4.1M
Q4 24
$-3.6M
$-3.3M
Q3 24
$-1.4M
$-3.0M
Q2 24
$142.1K
$-5.8M
Q1 24
$-698.0K
$-6.5M
Gross Margin
CVR
CVR
LCTX
LCTX
Q4 25
2.7%
Q3 25
18.1%
Q2 25
13.4%
Q1 25
22.9%
97.6%
Q4 24
-43.7%
94.6%
Q3 24
10.0%
99.0%
Q2 24
17.6%
96.9%
Q1 24
9.5%
93.2%
Operating Margin
CVR
CVR
LCTX
LCTX
Q4 25
-15.3%
-99.1%
Q3 25
0.9%
-102.9%
Q2 25
-5.7%
-715.4%
Q1 25
1.0%
-433.1%
Q4 24
-86.4%
-178.2%
Q3 24
-11.8%
-101.6%
Q2 24
1.3%
-416.7%
Q1 24
-11.5%
-461.3%
Net Margin
CVR
CVR
LCTX
LCTX
Q4 25
-19.3%
12.9%
Q3 25
0.9%
-809.0%
Q2 25
-5.4%
-1101.8%
Q1 25
5.5%
-275.6%
Q4 24
-88.0%
-114.1%
Q3 24
-20.8%
-80.3%
Q2 24
1.8%
-409.1%
Q1 24
-8.9%
-453.0%
EPS (diluted)
CVR
CVR
LCTX
LCTX
Q4 25
$0.00
Q3 25
$-0.13
Q2 25
$-0.13
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.02
Q2 24
$-0.03
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVR
CVR
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$1.7M
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$18.8M
$44.5M
Total Assets
$23.3M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVR
CVR
LCTX
LCTX
Q4 25
$1.7M
$55.8M
Q3 25
$1.7M
$40.5M
Q2 25
$1.2M
$42.3M
Q1 25
$765.6K
$47.9M
Q4 24
$2.2M
$47.8M
Q3 24
$2.2M
$32.7M
Q2 24
$2.6M
$38.5M
Q1 24
$2.7M
$43.6M
Total Debt
CVR
CVR
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CVR
CVR
LCTX
LCTX
Q4 25
$18.8M
$44.5M
Q3 25
$20.0M
$22.0M
Q2 25
$20.0M
$48.4M
Q1 25
$20.4M
$79.0M
Q4 24
$20.0M
$78.4M
Q3 24
$23.7M
$66.2M
Q2 24
$25.2M
$68.3M
Q1 24
$25.2M
$72.4M
Total Assets
CVR
CVR
LCTX
LCTX
Q4 25
$23.3M
$112.6M
Q3 25
$24.0M
$89.6M
Q2 25
$23.6M
$90.8M
Q1 25
$24.1M
$111.8M
Q4 24
$23.4M
$113.2M
Q3 24
$26.4M
$96.6M
Q2 24
$27.3M
$102.8M
Q1 24
$27.8M
$108.5M
Debt / Equity
CVR
CVR
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVR
CVR
LCTX
LCTX
Operating Cash FlowLast quarter
$116.4K
$-4.9M
Free Cash FlowOCF − Capex
$24.3K
$-5.3M
FCF MarginFCF / Revenue
0.4%
-79.9%
Capex IntensityCapex / Revenue
1.5%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-1.6M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVR
CVR
LCTX
LCTX
Q4 25
$116.4K
$-4.9M
Q3 25
$638.0K
$-3.6M
Q2 25
$28.2K
$-5.5M
Q1 25
$-2.0M
$-4.9M
Q4 24
$-60.1K
$-6.3M
Q3 24
$-58.2K
$-5.8M
Q2 24
$363.5K
$-5.2M
Q1 24
$-398.8K
$-5.8M
Free Cash Flow
CVR
CVR
LCTX
LCTX
Q4 25
$24.3K
$-5.3M
Q3 25
$492.1K
$-3.6M
Q2 25
$-22.8K
$-5.6M
Q1 25
$-2.1M
$-5.0M
Q4 24
$-118.1K
$-6.7M
Q3 24
$-368.9K
$-5.9M
Q2 24
$58.0K
$-5.2M
Q1 24
$-491.8K
$-5.8M
FCF Margin
CVR
CVR
LCTX
LCTX
Q4 25
0.4%
-79.9%
Q3 25
6.7%
-98.6%
Q2 25
-0.3%
-200.8%
Q1 25
-28.3%
-331.8%
Q4 24
-2.9%
-234.0%
Q3 24
-5.3%
-156.1%
Q2 24
0.7%
-371.2%
Q1 24
-6.3%
-403.1%
Capex Intensity
CVR
CVR
LCTX
LCTX
Q4 25
1.5%
6.0%
Q3 25
2.0%
0.3%
Q2 25
0.7%
0.5%
Q1 25
0.6%
6.5%
Q4 24
1.4%
12.7%
Q3 24
4.5%
3.0%
Q2 24
3.8%
3.6%
Q1 24
1.2%
2.6%
Cash Conversion
CVR
CVR
LCTX
LCTX
Q4 25
-5.73×
Q3 25
9.44×
Q2 25
Q1 25
-5.01×
Q4 24
Q3 24
Q2 24
2.56×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVR
CVR

Fastener$5.1M85%
Other$890.7K15%

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons